[1] |
HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
[2] |
ZENG H M, CHEN W Q, ZHENG R S, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
|
[3] |
周昌明, 莫淼, 袁晶, 等. 以医院登记为基础的20万例恶性肿瘤患者生存报告[J]. 中国癌症杂志, 2020, 30(1): 11-24.
|
|
ZHOU C M, MO M, YUAN J, et al. Report on 200 thousand cancer patients’ survival from a hospital-based cancer registry database[J]. China Oncol, 2020, 30(1): 11-24.
|
[4] |
American Joint Committee on Cancer. AJCC Cancer Staging Manual[M]. 8th Edition. Chicago: Springer, 2018.
|
[5] |
Shanghai Statistical Yearbook[EB/OL]. (2022-08-29)[2024-12-06]. https://tjj.sh.gov.cn/tjnj/rktjnj2020e.htm.
|
[6] |
DAVIES L, GILBERT WELCH H. Thyroid cancer survival in the United States: observational data from 1973 to 2005[J]. Arch Otolaryngol Head Neck Surg, 2010, 136(5): 440-444.
|
[7] |
DAL MASO L, TAVILLA A, PACINI F, et al. Survival of 86, 690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5[J]. Eur J Cancer, 2017, 77: 140-152.
|
[8] |
Office for National Statistics. Cancer survival in England: adult, stage at diagnosis and childhood-patients followed up to 2018[EB/OL]. (2019-08-12)[2024-12-06]. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/stageatdiagnosisandchildhoodpatientsfollowedupto2018#10-year-predicted-survival-estimates.
|
[9] |
American Society of Clinical Oncology (ASCO). Thyroid cancer: statistics[EB/OL]. (2024-08-23)[2024-12-06]. https://www.cancer.org/cancer/types/thyroid-cancer/detection-diagnosis-staging/survival-rates.html.
|
[10] |
ZITRICKY F, KOSKINEN A, SUNDQUIST K, et al. Survival in thyroid cancer in Sweden from 1999 to 2018[J]. Clin Epidemiol, 2024, 16: 659-671.
doi: 10.2147/CLEP.S467874
pmid: 39371051
|
[11] |
ZENG H M, ZHENG R S, SUN K X, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4(3): 203-213.
|
[12] |
TICHANEK F, FÖRSTI A, LISKA V, et al. Early mortality critically impedes improvements in thyroid cancer survival through a half century[J]. Eur J Endocrinol, 2023, 189(3): 355-362.
doi: 10.1093/ejendo/lvad117
pmid: 37675794
|
[13] |
LI P, DING Y, LIU M Y, et al. Sex disparities in thyroid cancer: a SEER population study[J]. Gland Surg, 2021, 10(12): 3200-3210.
doi: 10.21037/gs-21-545
pmid: 35070880
|
[14] |
GUO K, WANG Z Y. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(9): 5393-5403.
|
[15] |
KRUIJFF S, PETERSEN J F, CHEN P, et al. Patterns of structural recurrence in papillary thyroid cancer[J]. World J Surg, 2014, 38(3): 653-659.
doi: 10.1007/s00268-013-2286-0
pmid: 24149717
|
[16] |
SOUSA A, FERREIRA M, OLIVEIRA C, et al. Gender differential transcriptome in gastric and thyroid cancers[J]. Front Genet, 2020, 11: 808.
doi: 10.3389/fgene.2020.00808
pmid: 32849808
|
[17] |
KIM K H, ROBERTS C W M. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134.
doi: 10.1038/nm.4036
pmid: 26845405
|
[18] |
TRICARICO R, NICOLAS E, HALL M J, et al. X- and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis[J]. Clin Cancer Res, 2020, 26(21): 5567-5578.
doi: 10.1158/1078-0432.CCR-20-1741
pmid: 32732223
|
[19] |
KIM M J, CHOI S K, HONG S H, et al. Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1[J]. Int J Oncol, 2018, 53(1): 395-403.
doi: 10.3892/ijo.2018.4392
pmid: 29749437
|
[20] |
ZHANG L J, XIONG Y, NILUBOL N, et al. Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity[J]. Carcinogenesis, 2015, 36(4): 420-428.
doi: 10.1093/carcin/bgv001
pmid: 25576159
|
[21] |
HEO J, RYU H J, PARK H, et al. Mortality rate and causes of death in papillary thyroid microcarcinoma[J]. Endocrine, 2024, 83(3): 671-680.
|
[22] |
KIM K J, JANG S, KIM K J, et al. Actual causes of death in thyroid cancer patients in Korea: a Nationwide case control cohort study[J]. Eur J Endocrinol, 2020, 182(1): 103-110.
doi: 10.1530/EJE-19-0548
pmid: 31721722
|
[23] |
DU B B, WANG F, WU L M, et al. Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study[J]. Endocrine, 2021, 72(1): 179-189.
|
[24] |
ZHANG K, WANG X Y, WEI T, et al. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation[J]. Front Endocrinol (Lausanne), 2024, 15: 1347362.
|